ALKERMES | ALKS - Ebitda


ALKERMES reported $139.22M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
AbbVie USD 3.69B 1.68B Mar/2026
Acadia Pharmaceuticals USD -1.62M 21.94M Mar/2026
ALKERMES USD 139.22M 58.96M Jun/2026
Amgen USD 3.86B 1.28B Mar/2026
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Eli Lilly USD 10.29B 1.86B Mar/2026
Gilead Sciences USD 3.51B 489M Mar/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
J&J USD 8.27B 1.08B Mar/2026
Malin Corporation EUR -1.1M 200K Dec/2024
Merck USD -1.54B 7.84B Mar/2026
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Otsuka Holdings JPY 156.66B 56.89B Mar/2026
Pfizer USD 6.01B 18M Jun/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Vertex Pharmaceuticals USD 1.33B 130.5M Jun/2026